Eisai (Japan)

Japanese pharmaceutical company headquartered in Bunkyo, Tokyo, founded in 1941 and listed in Tokyo, which works to a human health care mission. Researches, develops, makes and sells prescription medicines with its main areas in neurology, where it produces donepezil for Alzheimer's disease, perampanel for epilepsy and lecanemab developed with Biogen, and in oncology, where lenvatinib is partnered with Merck & Co, together with a consumer health business, and runs research centres in Japan, the United States and Britain and plants in Japan, Asia, Europe and the Americas.